跳至主要内容
临床试验/CTRI/2012/01/002375
CTRI/2012/01/002375已完成2 期

Clinical Evaluation of Mahatriphaladya Ghrita in the Management of Allergic Conjunctivitis. - ACT- AC-2010

Department of AYUSH Ministry of Health Family Welfare Government of India0 个研究点目标入组 150 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
150

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1. Patients of either sex aged between 16-35years.
  • 2. Patients presenting with signs and symptoms of Allergic Conjunctivitis.
  • 3. Willing and able to participate for 16 weeks.

排除标准

  • 1. Patients having complications like marginal corneal ulcer, dacryocystitis, trachoma, kerato - conjunctivitis, Infective conjunctivitis, etc.
  • 2. Patients having genetic predisposition to allergy.
  • 3. Patients with concurrent serious Hepatic Dysfunction (defined as AST and/or ALT > 2 times of the upper normal limit) or Renal Dysfunction (defined as S. creatinine > 1.2mg/dl), uncontrolled Pulmonary Dysfunction (asthmatic and COPD patients) or other concurrent severe disease.
  • 4. Patients with poorly controlled Diabetes Mellitus (HbA1c > 10%)
  • 5. Patients with poorly controlled Hypertension ( > 160 / 100 mm Hg)
  • 6. Pregnant / lactating females
  • 7. Patients on steroids, oral contraceptive pills or estrogen replacement therapy.
  • 8. Smokers/Alcoholics and/or drug abusers
  • 9. Patients with evidence of malignancy
  • 10. Patients suffering from major systemic illness necessitating long term drug treatment (Rheumatoid arthritis, Psycho-Neuro- Endocrinal disorders, etc.)
  • 11. H/o hypersensitivity to the trial drug or any of its ingredients.
  • 12. Patients who have completed participation in any other clinical trial during the past six (06) months.
  • 13. Any other condition which the P.I. thinks may jeopardize the study.

研究者

发起方
Department of AYUSH Ministry of Health Family Welfare Government of India

相似试验